Print

ARCA biopharma's GencaroTM Atrial Fibrillation Data Selected for Presentation at American College of Cardiology 61st Annual Scientific Session & Expo  
3/20/2012 6:35:23 AM

BROOMFIELD, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for atrial fibrillation and other cardiovascular diseases, announced today that a Gencaro (bucindolol hydrochloride) abstract has been selected for moderated poster presentation at the American College of Cardiology 61st Annual Scientific Sessions & Expo, being held March 24-27, 2012 in Chicago, Illinois.
//-->